Literature DB >> 10490031

Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.

M S Finnin1, J R Donigian, A Cohen, V M Richon, R A Rifkind, P A Marks, R Breslow, N P Pavletich.   

Abstract

Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression. HDACs are involved in cell-cycle progression and differentiation, and their deregulation is associated with several cancers. HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumour effects, as they can inhibit cell growth, induce terminal differentiation and prevent the formation of tumours in mice models, and they are effective in the treatment of promyelocytic leukemia. Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homologue from the hyperthermophilic bacterium Aquifex aeolicus, that shares 35.2% identity with human HDAC1 over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA. The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition. The residues that make up the active site and contact the inhibitors are conserved across the HDAC family. These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumour agents.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10490031     DOI: 10.1038/43710

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  419 in total

1.  A fully automatic evolutionary classification of protein folds: Dali Domain Dictionary version 3.

Authors:  S Dietmann; J Park; C Notredame; A Heger; M Lappe; L Holm
Journal:  Nucleic Acids Res       Date:  2001-01-01       Impact factor: 16.971

Review 2.  Chromatin modification and disease.

Authors:  C A Johnson
Journal:  J Med Genet       Date:  2000-12       Impact factor: 6.318

Review 3.  Macrocyclic histone deacetylase inhibitors.

Authors:  Sandra C Mwakwari; Vishal Patil; William Guerrant; Adegboyega K Oyelere
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

4.  Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5.

Authors:  X Zhou; V M Richon; R A Rifkind; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 5.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

Review 6.  Structural aspects of HDAC8 mechanism and dysfunction in Cornelia de Lange syndrome spectrum disorders.

Authors:  Matthew A Deardorff; Nicholas J Porter; David W Christianson
Journal:  Protein Sci       Date:  2016-09-16       Impact factor: 6.725

7.  Quantitative Analysis of the Proteome Response to the Histone Deacetylase Inhibitor (HDACi) Vorinostat in Niemann-Pick Type C1 disease.

Authors:  Kanagaraj Subramanian; Navin Rauniyar; Mathieu Lavalleé-Adam; John R Yates; William E Balch
Journal:  Mol Cell Proteomics       Date:  2017-08-31       Impact factor: 5.911

8.  Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic alpha/beta-tetrapeptide architectures.

Authors:  Ana Montero; John M Beierle; Christian A Olsen; M Reza Ghadiri
Journal:  J Am Chem Soc       Date:  2009-03-04       Impact factor: 15.419

Review 9.  Dietary agents as histone deacetylase inhibitors.

Authors:  Melinda C Myzak; Emily Ho; Roderick H Dashwood
Journal:  Mol Carcinog       Date:  2006-06       Impact factor: 4.784

Review 10.  Molecular brake pad hypothesis: pulling off the brakes for emotional memory.

Authors:  Annie Vogel-Ciernia; Marcelo A Wood
Journal:  Rev Neurosci       Date:  2012       Impact factor: 4.353

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.